Alumni Ventures

Epicore Biosystems, Inc. is a Cambridge, Massachusetts-based company founded in 2017 that specializes in developing and commercializing a wearable microfluidic sensing platform. This innovative technology analyzes small droplets of sweat directly from the skin to provide insights into health, hydration, and athletic performance. The platform is designed to measure various biomarkers, including proteomics and inflammatory markers, allowing for personalized management of health and nutrition. Epicore's approach leverages over two decades of research in microfluidics and soft materials conducted by leading experts at Northwestern University. By offering a non-invasive and cost-effective solution, Epicore aims to enhance athletic performance and improve overall health monitoring for users.

TAU Systems specializes in advanced medical imaging technology and the development of compact particle accelerators. The company has created innovative laser technology systems that significantly reduce the size of traditional particle accelerators from miles to meters. Their offerings include specialized x-ray free-electron lasers, which merge the functionality of large accelerators into a more manageable format. This technology provides vital beam-time access for various industries, facilitating advancements in nuclear, biotechnology, and medical research. By focusing on miniaturization and efficiency, TAU Systems aims to enhance the accessibility and utility of cutting-edge research methods.

Springbok Analytics offers an AI-powered software platform that transforms MRIs into three-dimensional analyses of muscle to enable true precision. Springbok Analytics' advanced imaging technology identifies and measures each individual muscle, providing data to scientists, physical therapists, athletic trainers, and physicians to evaluate muscle function in relation to performance and injury management. The technology has numerous applications, including injury management, performance enhancement, and the treatment of musculoskeletal conditions.

Precision Neuroscience is a company focused on developing advanced brain-computer interface technology aimed at offering innovative treatments for the approximately one billion individuals worldwide affected by neurological disorders. Founded in 2021 and based in New York, the company's technology is characterized by its minimally invasive design, safety for removal, and capacity for processing substantial data. This platform enables medical professionals to establish a direct connection between the human brain and artificial intelligence, potentially transforming the landscape of neurological care.

MetaSight Diagnostics, a health technology company, is on a mission to develop affordable and precise liquid biopsy diagnostics for the early detection of a wide range of chronic and acute diseases by leveraging proprietary mass spectrometry technologies (metabolomics, lipidomics, and proteomics).

CytoVale, Inc. is a medical technology company based in San Francisco, California, established in 2012. The company specializes in developing biomarkers that leverage the mechanical properties of individual cells, a field known as mechanomics. By utilizing microfluidics technology, CytoVale can efficiently route and physically probe single cells to measure multiple biomarkers simultaneously. This innovative approach aims to enhance early detection of immune-mediated diseases, particularly sepsis, thereby improving patient outcomes and reducing treatment costs. CytoVale's integration of cell mechanics with machine learning positions it at the forefront of revolutionizing diagnostic practices in healthcare.

Centaur Labs specializes in medical data annotation services, aimed at enhancing medical decision-making and diagnostics. The company utilizes a platform that connects a global network of students and professionals, who compete to provide high-quality data labeling. This collaborative model ensures exceptional accuracy and scalability in annotating medical and scientific data. By analyzing medical cases and labeling data effectively, Centaur Labs contributes to the development of advanced medical AI technologies, ultimately helping patients achieve better healthcare outcomes while potentially reducing costs.

AminoChain operates a blockchain-based platform that enhances the management of biosamples by connecting data from healthcare companies. The platform allows users to oversee bio-sample inventories while ensuring ownership of their assets. It facilitates collaboration among stakeholders through an integrated solution that encompasses sample procurement, agreements, and payments. Additionally, AminoChain focuses on tokenizing and incentivizing stem cell donations, providing donors with compensation for their contributions and offering biobanks a secure method for inventory management.

GC Therapeutics specializes in synthetic biology to efficiently program patient-derived stem cells into various cell types. The company has developed a proprietary platform that integrates synthetic biology and artificial intelligence, enabling streamlined manufacturing and improved quality of cell therapies. Their approach allows for the rapid differentiation of pluripotent stem cells, creating unique SuperCells™ customized for specific medical conditions. The foundational technology was developed in Professor George Church's lab at Harvard Medical School, and the team at GC Therapeutics comprises dedicated biologists and tissue engineers focused on translating this innovative method into practical therapies for patients.

InGel Therapeutics is a Cambridge, Massachusetts-based company founded in 2021 that focuses on developing stem cell therapeutics and biodegradable polymers. The company specializes in engineered cell therapy aimed at addressing neuroprotective pathways to treat retinal degeneration. By utilizing stem cells and their secretome, InGel Therapeutics seeks to provide neuroprotection for blinding diseases such as retinitis pigmentosa and macular degeneration. Their innovative approach involves using biodegradable polymers to isolate proteins of neuroprotective significance, first in vitro and subsequently in vivo, thereby enabling healthcare professionals to effectively treat patients suffering from retinal degeneration.

Modicus Prime specializes in developing advanced computer vision software and self-service artificial intelligence tools tailored for the life sciences sector. Their technology automates the analysis of biologics images, addressing challenges related to product quality failures that can result in significant costs, legal issues, and waste in research and manufacturing processes. The platform facilitates the integration of diverse life sciences data, enabling users to detect anomalies, monitor operations, and enhance decision-making. By allowing clients to execute cutting-edge research and production, train algorithms on specific data sets, and harness insights through self-service capabilities, Modicus Prime effectively addresses the evolving data challenges in the life sciences industry, including continuous manufacturing and intelligent monitoring.

Magnetic Insight, Inc. specializes in magnetic particle imaging (MPI), an innovative imaging technology that utilizes iron oxide nanoparticle tracers and time-varying magnetic fields. The company has developed several products, including the MOMENTUM imager, a pre-clinical MPI solution that produces high-quality images through advanced magnet geometry and a proprietary reconstruction process. Additionally, Magnetic Insight offers VivoTrax, a nanoparticle designed for cell tracking and as a blood pool agent in pre-clinical studies, and Hyper, an add-on module for the MOMENTUM system that assists in identifying treatment targets and administering localized magnetic hyperthermia. Another product, Relax, serves as a particle relaxometry module. Founded in 2012 and headquartered in Alameda, California, Magnetic Insight aims to enhance preclinical diagnostic research by enabling quantitative cell tracking, imaging of vascular functions, and visualization of various biological processes, thereby addressing challenges in clinical and translational research.

An emerging genomic and data science company, developing novel drugs based on naturally occurring resistance mechanisms

Atom Computing Inc. is a company based in Berkeley, California, that focuses on manufacturing scalable quantum computers utilizing individual atoms. Founded in 2018, the company harnesses the quantum mechanical properties of atoms to process information and address complex problems that traditional computers cannot solve. Atom Computing's technology allows for the optical control, scaling, and stabilization of these atoms, facilitating efficient quantum calculations in various fields, including drug design, computational chemistry, and general computing. Through its innovative approach, Atom Computing aims to advance the development of quantum technology and expand its applications across multiple industries.

Bionaut Labs, Inc. is a biotechnology company based in Palo Alto, California, founded in 2016. The company specializes in developing a novel intra-tissue navigation platform utilizing Bionaut nano/micro robots that operate within the body. This innovative technology enables precise anatomical targeting for the treatment of central nervous system disorders, offering a new approach to precision medicine. By employing remote-controlled micro-robots, Bionaut Labs enhances the development of therapeutics, making advanced technologies like gene therapy and CRISPR-Cas9 feasible in challenging clinical scenarios. The Bionaut platform allows medical professionals to access any anatomic location within the body, facilitating the automation of complex procedures while eliminating the need for external incisions, thereby improving patient outcomes for those with limited treatment options.

ParcelBio is a biotechnology company specializing in the development of a novel, programmable method for safely and precisely delivering messenger RNA (mRNA) to diverse cell types within the body. Their technology aims to create targeted, potent, and durable RNA therapeutics, with the potential to treat a wide range of diseases, including cancer, genetic disorders, and infectious diseases.

Nanochon is focused on creating innovative implantable medical devices designed to address cartilage damage in joints. Utilizing advanced 3D printing techniques and a unique nanomaterial, the company aims to develop solutions that not only replace lost and damaged cartilage but also promote the growth of new tissue. This approach allows medical practitioners to access cost-effective and on-demand devices that enhance treatment outcomes, particularly for young and active patients suffering from knee injuries and diseases. Through its technology, Nanochon seeks to improve the overall quality of care in orthopedics.

YonedaLabs is a developer of AI-based software designed to assist chemists in optimizing various reaction parameters, including temperature, concentration, and catalysts. Their platform aims to enhance the efficiency of chemical laboratories by streamlining the process involved in drug and material production. By leveraging artificial intelligence, YonedaLabs enables businesses to accelerate their research and development efforts, ultimately improving outcomes in the field of chemistry.

Nectero Medical is a clinical-stage biotechnology company based in Dover, Delaware, that focuses on treating mid-sized abdominal aortic aneurysms. Founded in 2017, the company has developed an innovative treatment designed to stabilize the growth of aneurysms and prevent their rupture. This treatment delivers a compound containing a stabilizer agent directly to the aneurysm site, which helps inhibit further breakdown and strengthens the vessel wall. By providing a safer intervention option, Nectero Medical aims to enable patients to receive timely care, significantly delaying or preventing the need for major endovascular or surgical repair.

HelixNano is a biotechnology company focused on leveraging artificial intelligence and synthetic biology to develop innovative solutions for genetic diseases. Initially concentrating on cancer vaccines, the company is now pivoting to create COVID-19 vaccine candidates that prioritize precision and safety. HelixNano's platform enables the reliable expression of transgenes in humans, facilitating advancements in gene therapies and genome engineering. The company aims to not only address the current COVID-19 pandemic but also to develop vaccines that provide protection against all future coronaviruses. Through its work, HelixNano seeks to enable previously unattainable applications in both human and non-human biology, ultimately improving patient outcomes across a range of diseases.

Century Health is a technology company that specializes in accelerating drug development and commercialization. It achieves this by harnessing the power of artificial intelligence (AI) to analyze real-world clinical data, which is often siloed and difficult to access. The company's platform connects to various disease-specific datasets, cleans and standardizes the data using AI, and enables researchers to efficiently analyze this real-world data. This process helps answer critical questions more rapidly, supports the research community, and ensures patient privacy is protected.

BE Therapeutics is a biotechnology company specializing in regenerative medicine. It develops innovative therapies aimed at repairing and restoring damaged brain and spinal cord tissue, focusing on engineering functional tissue to treat neurological conditions and spinal cord injuries.

Cyrus Biotechnology, Inc. is a Seattle-based company that specializes in developing advanced software for protein structure prediction and design. Founded in 2014, it offers several key products, including Rosetta, a tool designed to create biologically active proteins for various medical applications such as treating brain cancer and addressing Celiac Disease. The company also provides Cyrus Bench, an enterprise version of Rosetta that includes a comprehensive suite of bio-molecular computation tools. Additionally, Cyrus Biotechnology offers specialized services like Cyrus CryoEM, which focuses on structure refinement and model building for complex biomolecular structures. Its innovative software solutions cater to pharmaceutical companies, biotech firms, and startups engaged in discovering therapeutics and developing novel consumer products.

Pendulum Therapeutics Inc. is a microbiome-focused company based in San Francisco that specializes in developing medical probiotics and prebiotics aimed at managing chronic illnesses, particularly type 2 diabetes. The company's flagship product, Pendulum Glucose Control, was introduced in 2020 and has demonstrated effectiveness in lowering blood sugar spikes and reducing A1C levels, as evidenced by published clinical trials. Pendulum utilizes evidence-based microbiome science and DNA sequencing to create targeted interventions, allowing clinicians to identify specific microbiome markers for disease treatment. Founded in 2013, Pendulum holds 13 patents and has 42 pending, with significant backing from prominent investors. The company sells its products online, focusing on improving healthcare through innovative microbiome therapies.

Epicore Biosystems, Inc. is a Cambridge, Massachusetts-based company founded in 2017 that specializes in developing and commercializing a wearable microfluidic sensing platform. This innovative technology analyzes small droplets of sweat directly from the skin to provide insights into health, hydration, and athletic performance. The platform is designed to measure various biomarkers, including proteomics and inflammatory markers, allowing for personalized management of health and nutrition. Epicore's approach leverages over two decades of research in microfluidics and soft materials conducted by leading experts at Northwestern University. By offering a non-invasive and cost-effective solution, Epicore aims to enhance athletic performance and improve overall health monitoring for users.

Granata Bio is a biotechnology company established in 2018 that specializes in identifying and developing therapeutics for fertility patients. The company focuses on creating a comprehensive portfolio of fertility-related treatments and leverages its expertise in commercialization, late-stage clinical trials, and regulatory development. Granata Bio aims to address significant challenges faced by medical professionals in fertility treatment. Recently, the company announced a partnership with IBSA Institut Biochimique to co-develop a novel subcutaneous progesterone solution, further enhancing its commitment to improving fertility care.

Earli is a company focused on developing innovative cancer treatment devices that utilize synthetic biomarkers for early cancer detection. The company's approach involves a novel gene therapy technique known as Synthetic Biopsy, which prompts cancer cells to produce synthetic, non-human biomarkers. These biomarkers can be detected through various means, including blood, urine, or breath, allowing for timely tracking and treatment of cancer. By facilitating the early identification of cancer when it is still homogeneous, Earli aims to significantly enhance survival rates. Their technology not only aids in detection but is also applicable for therapeutic interventions, thereby personalizing treatment and improving patient outcomes.

Anthology is an evolution company that generates diverse genomes to scale and digitalize biomanufacturing.

Featureform develops machine learning tools specifically for pharmaceutical and biotechnology companies. The company offers an open-source virtual feature store that enables data scientists to define, manage, and serve machine learning features throughout their organizations. Its platform provides a unified interface to connect, transform, and join both streaming and batch data. Featureform facilitates the discovery and integration of features created by various teams, allowing them to share and enhance their models. Additionally, the platform includes capabilities to monitor and analyze features, as well as to freeze them, which allows teams to concentrate on building models to support their data pipelines effectively.

Capra Biosciences is a biotechnology company focused on the efficient and low-carbon production of everyday chemicals through innovative bioreactor technology. The company has developed a biofilm bioreactor platform that aims to enhance the bio-manufacturing process by significantly reducing downstream processing requirements and associated costs. This technology facilitates the production of a variety of bio-based chemicals, including hydrophobic products like retinol and performance lubricants, thus advancing sustainable practices in the chemical industry.

CytoVale, Inc. is a medical technology company based in San Francisco, California, established in 2012. The company specializes in developing biomarkers that leverage the mechanical properties of individual cells, a field known as mechanomics. By utilizing microfluidics technology, CytoVale can efficiently route and physically probe single cells to measure multiple biomarkers simultaneously. This innovative approach aims to enhance early detection of immune-mediated diseases, particularly sepsis, thereby improving patient outcomes and reducing treatment costs. CytoVale's integration of cell mechanics with machine learning positions it at the forefront of revolutionizing diagnostic practices in healthcare.

Jona is a technology startup focused on leveraging artificial intelligence to explore the relationship between the microbiome and overall health. The company has developed an advanced microbiome profiling platform that utilizes deep metagenomics technology to analyze a wide range of microorganisms, including bacteria, fungi, viruses, and protists. This analysis creates a comprehensive map that links these microorganisms to various health conditions, symptoms, and food sensitivities. By interpreting microbiome test results, Jona aims to empower individuals to proactively manage their health through informed recommendations on diet, exercise, sleep, and other treatments, addressing the growing prevalence of chronic illnesses.

Ummino is a company based in Raleigh, North Carolina, that specializes in precision fermentation technology for the fortified food and beverage sectors. Founded in 2019, Ummino’s innovative technology allows customers to convert common ingredients into high-value functional foods by unlocking rare compounds and enhancing taste and nutritional value. The company's focus on optimizing these properties positions it to significantly impact the food industry, particularly in the realm of functional and fortified products.

Eigen Therapeutics is a biotechnology company dedicated to developing innovative therapies that enhance the detection and treatment of cancer. The company specializes in "priming" therapies, which help targeted treatments become more effective by addressing cancer heterogeneity and increasing the vulnerability of cancer cells, while simultaneously improving the resilience of healthy cells. Eigen is creating a high-throughput discovery platform that combines biology and engineering, utilizing proprietary machine learning algorithms to identify new drug classes and therapeutic approaches. This platform incorporates robotic systems, laboratory operations software, and machine learning analysis pipelines, all developed in-house. By focusing on combination therapeutics that improve efficacy and reduce toxicity, Eigen aims to provide physicians with access to novel treatments for patients with unmet medical needs, ultimately striving to enhance patient outcomes and save lives.

Ruby Bio is a biosynthesis platform focused on the production of complex, biodegradable, and non-toxic molecules. Utilizing naturally occurring yeast, the company transforms low-cost sugars into high-value products. This innovative approach allows Ruby Bio to support the creation of sustainable alternatives in personal care, home care, food, and beverage industries. By harnessing the power of biosynthesis, Ruby Bio aims to contribute to environmentally friendly solutions while addressing the growing demand for sustainable products.

TFC Therapeutics is a biotechnology company focused on developing innovative biologics aimed at addressing key drivers of cancer recurrence and metastasis. The company’s technology utilizes monoclonal antibodies that specifically bind to receptors on the surface of tumor-initiating cells (TMH cells). This binding action activates the immune system to target and destroy these cells, offering the potential for new cancer treatments. By concentrating on the elimination of TMH cells, TFC Therapeutics seeks to provide effective solutions for improving patient outcomes in cancer care.

VenoStent, Inc. is a clinical-stage tissue engineering company based in Nashville, Tennessee, with an additional office in Houston, Texas. Founded in 2017, it specializes in the development of bioresorbable smart polymers designed to enhance vascular surgery outcomes. The company’s primary product, SelfWrap, is a perivascular wrap that functions as an external stent, providing mechanical support to veins and promoting outward growth. This innovative technology aims to reduce complications at the vein-artery junction in dialysis patients, particularly by minimizing vein collapse and improving the usability of arteriovenous fistulas (AVF). By utilizing a new class of shape-memory polymers that do not require sutures, VenoStent's approach reduces surgery time and lowers the risk of infection, ultimately enhancing the quality and length of life for patients with chronic kidney disease undergoing hemodialysis.

Ossium Health, Inc. is engaged in the development and manufacturing of cell therapy products aimed at treating leukemia, other blood cancers, and tissue damage, as well as addressing radiation poisoning. The company offers a range of innovative therapies, including HPC, Marrow, which features HLA-matched bone marrow stem cells for hematopoietic reconstitution in blood cancer patients; Chimera, which enhances organ transplantation; and Chymalis, composed of mesenchymal stem cells that promote the healing of damaged bone and muscle tissue. Additionally, Ossium provides bone marrow cells for research purposes in oncology and immunology. Founded in 2016 and headquartered in San Francisco, California, Ossium Health focuses on improving health outcomes and longevity through advanced bioengineering techniques.

3X Genetics specializes in developing medical screening solutions aimed at identifying genetic disorders, particularly in infants and children. The company's technology focuses on screening for conditions such as myotonic dystrophy and other trinucleotide repeat disorders that lead to progressive muscle weakness. By offering these medical technologies, 3X Genetics enables healthcare professionals to proactively identify potential genetic issues, ultimately helping to prevent the birth of children affected by genetic diseases.

MEND is a life sciences company dedicated to advancing health and recovery through targeted clinical nutrition and medical food interventions. The company focuses on researching and developing products that enhance patient outcomes in various contexts, including injury recovery, surgical recovery, aging, and physical performance. MEND's solutions have been widely adopted by hospitals, health systems, and professional sports teams across major leagues, as well as by the elite forces of the US Military. Through its commitment to ongoing research and development, MEND aims to empower caregivers and improve health outcomes for individuals facing diverse health challenges.

Synteny.Ai Syntney decodes the signals of immune repertoires to help biotech research and pharma companies with disease discoveries.

Iolyx Therapeutics is a biotechnology company focused on developing solutions for ocular diseases. Operating at the intersection of immunology and ophthalmology, the company aims to transform the standard of care for these conditions. Iolyx Therapeutics utilizes an innovative platform that provides tailored formulations for precise delivery to targeted eye tissues. Its products are designed to address ocular inflammation directly at its source, affecting both the front and back of the eye. This approach seeks to enhance efficacy, safety, and convenience for patients suffering from various ocular conditions.

Jona is a technology startup focused on leveraging artificial intelligence to explore the relationship between the microbiome and overall health. The company has developed an advanced microbiome profiling platform that utilizes deep metagenomics technology to analyze a wide range of microorganisms, including bacteria, fungi, viruses, and protists. This analysis creates a comprehensive map that links these microorganisms to various health conditions, symptoms, and food sensitivities. By interpreting microbiome test results, Jona aims to empower individuals to proactively manage their health through informed recommendations on diet, exercise, sleep, and other treatments, addressing the growing prevalence of chronic illnesses.

Dimension Inx Corp. focuses on designing and developing three-dimensional (3D) printable materials and painted objects for research and commercial applications. The company specializes in creating regenerative microenvironments that aid the body in self-healing. Its biomaterials platform incorporates a complex interplay of material composition, microstructure, and microarchitecture to enhance biofunctionality. Dimension Inx offers a range of products, including Hyperelastic Bone for bone regeneration, 3D printable elastomers, bioactive ceramics, and solutions for soft tissue regeneration. Founded in 2016 and based in Chicago, Illinois, the company aims to provide innovative therapeutic products that restore tissue and organ function, potentially reducing the need for organ transplantation through advanced bio-fabrication processes.

Featureform develops machine learning tools specifically for pharmaceutical and biotechnology companies. The company offers an open-source virtual feature store that enables data scientists to define, manage, and serve machine learning features throughout their organizations. Its platform provides a unified interface to connect, transform, and join both streaming and batch data. Featureform facilitates the discovery and integration of features created by various teams, allowing them to share and enhance their models. Additionally, the platform includes capabilities to monitor and analyze features, as well as to freeze them, which allows teams to concentrate on building models to support their data pipelines effectively.

Precision Neuroscience is a company focused on developing advanced brain-computer interface technology aimed at offering innovative treatments for the approximately one billion individuals worldwide affected by neurological disorders. Founded in 2021 and based in New York, the company's technology is characterized by its minimally invasive design, safety for removal, and capacity for processing substantial data. This platform enables medical professionals to establish a direct connection between the human brain and artificial intelligence, potentially transforming the landscape of neurological care.

Gilgamesh Pharmaceuticals, Inc. is a preclinical biotechnology company based in New York that specializes in developing novel psychotropic drugs aimed at treating mental illnesses. Established in 2019, the company focuses on creating innovative compounds that enhance the therapeutic benefits of classic psychedelics while improving safety, tolerability, duration, and efficacy. Gilgamesh addresses the growing global mental health crisis by providing treatments for various neuropsychiatric conditions, including depression, anxiety, substance use disorders, and stress-related issues. Through a combination of medicinal chemistry and drug development expertise, the company aims to accelerate the availability of effective therapies, ultimately improving the quality of life for individuals suffering from central nervous system disorders.

Modicus Prime specializes in developing advanced computer vision software and self-service artificial intelligence tools tailored for the life sciences sector. Their technology automates the analysis of biologics images, addressing challenges related to product quality failures that can result in significant costs, legal issues, and waste in research and manufacturing processes. The platform facilitates the integration of diverse life sciences data, enabling users to detect anomalies, monitor operations, and enhance decision-making. By allowing clients to execute cutting-edge research and production, train algorithms on specific data sets, and harness insights through self-service capabilities, Modicus Prime effectively addresses the evolving data challenges in the life sciences industry, including continuous manufacturing and intelligent monitoring.

Eigen Therapeutics is a biotechnology company dedicated to developing innovative therapies that enhance the detection and treatment of cancer. The company specializes in "priming" therapies, which help targeted treatments become more effective by addressing cancer heterogeneity and increasing the vulnerability of cancer cells, while simultaneously improving the resilience of healthy cells. Eigen is creating a high-throughput discovery platform that combines biology and engineering, utilizing proprietary machine learning algorithms to identify new drug classes and therapeutic approaches. This platform incorporates robotic systems, laboratory operations software, and machine learning analysis pipelines, all developed in-house. By focusing on combination therapeutics that improve efficacy and reduce toxicity, Eigen aims to provide physicians with access to novel treatments for patients with unmet medical needs, ultimately striving to enhance patient outcomes and save lives.

Axoft is a company focused on developing advanced implantable electronics that enhance communication between the brain and machines. Its flagship technology consists of bioinspired implants made from ultra-flexible plastic mesh, which provides a softer alternative to traditional plastic and silicone implants. This innovative design allows for scalability and the integration of multiple sensors within a single implant, closely matching the brain's mechanical properties. Axoft's implants aim to improve clinical outcomes for patients suffering from neurodegenerative conditions, such as Parkinson's disease, thereby transforming individual health and overall human experience.

SURGE Therapeutics is dedicated to enhancing cancer patient survival through innovative approaches in immunotherapy. The company has developed a proprietary injectable biodegradable hydrogel designed for the prolonged and localized release of cancer immunotherapy following surgical tumor resection. By targeting the administration of treatment to specific areas at the optimal time, SURGE Therapeutics aims to improve the effectiveness of immunotherapy, allowing for both intravenous and intratumoral injections. This technology seeks to disrupt traditional cancer treatment paradigms and provide better outcomes for patients.

Nanopath Inc. is a molecular diagnostics company focused on enhancing women's health through rapid and precise testing. By utilizing advancements in bioengineering and nanotechnology, the company specializes in the sensitive detection of viral, bacterial, and fungal pathogens without relying on nucleic acid amplification techniques. This innovative approach allows for the delivery of granular and clinically actionable information, thereby improving traditional testing methodologies and enabling healthcare providers to make informed decisions more swiftly.

Arable Labs, Inc. specializes in developing a solar-powered Internet of Things (IoT) device equipped with advanced sensors for in-field crop monitoring. This technology allows farmers to digitize and optimize their agricultural decisions by providing critical data about the impact of weather and other factors on crop yield, quality, and harvest timing. Arable's integrated system combines unique spectral and thermal sensors with agronomic modeling and software tools, enabling users to monitor crop development and identify stressors such as water or nutrient deficiencies. The platform serves a diverse clientele, including farmers, agronomists, researchers, food processors, and agricultural enterprises, facilitating real-time insights and predictive analytics that enhance productivity and sustainability. Established in 2014, Arable is headquartered in San Francisco, California, with an additional office in Princeton, New Jersey. The company has received various accolades, highlighting its innovation in agricultural technology.

Magnetic Insight, Inc. specializes in magnetic particle imaging (MPI), an innovative imaging technology that utilizes iron oxide nanoparticle tracers and time-varying magnetic fields. The company has developed several products, including the MOMENTUM imager, a pre-clinical MPI solution that produces high-quality images through advanced magnet geometry and a proprietary reconstruction process. Additionally, Magnetic Insight offers VivoTrax, a nanoparticle designed for cell tracking and as a blood pool agent in pre-clinical studies, and Hyper, an add-on module for the MOMENTUM system that assists in identifying treatment targets and administering localized magnetic hyperthermia. Another product, Relax, serves as a particle relaxometry module. Founded in 2012 and headquartered in Alameda, California, Magnetic Insight aims to enhance preclinical diagnostic research by enabling quantitative cell tracking, imaging of vascular functions, and visualization of various biological processes, thereby addressing challenges in clinical and translational research.

Swing Therapeutics focuses on developing innovative digital therapeutics aimed at helping individuals with chronic conditions. The company collaborates with leading researchers to create evidence-based treatments that enhance patient empowerment and control over their health. By offering novel prescription digital therapeutics, Swing supports patients in managing their illnesses more effectively, ultimately fostering improved health outcomes and promoting a more vibrant quality of life.

Mozza is a Los Angeles-based company founded in 2018 that specializes in developing plant-based cheese products. The company focuses on creating dairy-identical cheese using plant proteins, aiming to replicate the taste, melt, and stretch of traditional animal-based cheese. Mozza's mission is to provide consumers with a viable alternative to dairy cheese, offering products that are indistinguishable from their animal-derived counterparts. By leveraging advancements in food science, Mozza seeks to revolutionize the cheese industry and cater to the growing demand for plant-based food options.

SCiFi Foods is a food technology company focused on producing cultivated meat that combines lab-grown beef cells with plant-based ingredients to create burgers that closely replicate the taste of traditional beef. The company aims to provide a sustainable and ethical alternative to conventional meat by utilizing bioengineering techniques to grow meat cells without relying on animal farming. SCiFi Foods has achieved significant advancements, including the successful growth of beef cells in suspension, which has the potential to drastically reduce production costs. Founded by CEO Joshua March and CTO Kasia Gora, PhD, the company has attracted $29 million in funding from prominent investors, positioning it for future growth in the alternative protein market.

Oobli specializes in the development of healthy, protein-based sweeteners sourced from exotic plants. These unique compounds offer a flavorful experience without the calories typically associated with sugar, making them a suitable alternative for health-conscious consumers. The protein sweeteners are produced through fermentation, ensuring they have no glycemic impact and do not disrupt the gut microbiome. Oobli has successfully obtained regulatory approvals, including FDA "no questions" letters and GRAS status for several of its proteins, reinforcing their commitment to safety and quality. By providing a delicious and low-calorie option, Oobli aims to transform the way individuals approach sweeteners, allowing for healthier choices in everyday consumption.

Unicorn Biotechnologies is developing a next-generation biomanufacturing platform to power the cell-based manufacturing revolution, starting with cultivated meat. By providing a clear path to affordably and rapidly scale cultivated meat, we will improve human and planetary health and drive the transition to animal-free agriculture.

American Gene Technologies International Inc., established in 2007 and based in Rockville, Maryland, is a biotechnology company specializing in gene and cell therapeutics. It develops a lentiviral platform with broad applications, including large and orphan indications, infectious diseases, immuno-oncology, and monogenic disorders. The company's portfolio includes a lead candidate for an HIV functional cure, a novel immuno-oncology approach to stimulate gamma-delta T cells, and a synthetic gene for treating Phenylketonuria (PKU). AGT aims to create long-term value for patients, society, and investors by developing and testing cutting-edge gene therapies to cure some of humanity's worst diseases.

Concerto Biosciences specializes in rebuilding microbial communities to enhance human health and environmental sustainability. The company has developed an ultra-high-throughput platform capable of measuring millions of microbial interactions, enabling the mapping of complex inter-species networks that dictate community behavior. This innovation allows Concerto to create "ensembles," which are specific combinations of microbes that collaboratively promote the recovery of damaged microbial ecosystems. By focusing on these microbial ensembles, Concerto aims to address critical global issues across various sectors, including agriculture, healthcare, and industry. The company's pioneering work positions it as a leader in the development of microbial solutions, fundamentally changing how humanity interacts with microbial life.

Satellite Bio is a company that specializes in cell therapy, regenerative medicine, synthetic biology, cell biology, and tissue engineering. It is dedicated to developing a therapeutic platform aimed at creating innovative cell therapies to address complex diseases. The company’s primary focus is on the design and implementation of proprietary, off-the-shelf, implantable satellite organs, which serve as living therapeutic solutions. These satellite organs are intended to improve the lives of millions of patients suffering from serious health conditions.

Epicore Biosystems, Inc. is a Cambridge, Massachusetts-based company founded in 2017 that specializes in developing and commercializing a wearable microfluidic sensing platform. This innovative technology analyzes small droplets of sweat directly from the skin to provide insights into health, hydration, and athletic performance. The platform is designed to measure various biomarkers, including proteomics and inflammatory markers, allowing for personalized management of health and nutrition. Epicore's approach leverages over two decades of research in microfluidics and soft materials conducted by leading experts at Northwestern University. By offering a non-invasive and cost-effective solution, Epicore aims to enhance athletic performance and improve overall health monitoring for users.

Verge Genomics is a biotechnology company focused on transforming drug discovery for neurodegenerative diseases through the application of artificial intelligence. Founded by experts in machine learning and seasoned drug developers in neuroscience, the company aims to leverage advances in computational genomics and insights into brain science to identify promising therapeutic targets. Its drug discovery platform utilizes machine learning algorithms to analyze large datasets, enabling the identification of effective drugs and accelerating the development of life-saving treatments. By improving the efficiency of the drug development process, Verge Genomics seeks to enhance patient outcomes and reduce the overall costs associated with pharmaceutical development.

Droplette Inc., founded in 2017 and based in Boston, Massachusetts, specializes in the development of a needle-free skincare device that utilizes a patent-pending transdermal delivery system. This innovative technology allows for the delivery of drugs up to 60% larger than traditional treatments, penetrating deeply into the skin over large surface areas. The device is designed to be painless, contact-free, and portable, generating no disposables. Initially aimed at delivering antibiotics for serious skin conditions such as ulcers and infections, Droplette also envisions future applications for localized delivery of chemotherapeutics for skin cancer and anti-aging treatments. By enabling effective skincare without harmful chemicals, Droplette aims to transform skin health through scientific advancement.

Transcend Therapeutics, Inc., established in 1992 in Waltham, Massachusetts, is a clinical-stage company focused on developing pharmaceuticals to address diseases associated with oxidative stress and tissue damage. The company aims to create psychoactive medicines targeting specific brain regions involved in neuropsychiatric disorders. By doing so, Transcend Therapeutics seeks to enable healthcare professionals to facilitate positive changes in brain function and behavior for patients suffering from these conditions.

GRO Biosciences is focused on developing advanced protein therapeutics by utilizing innovative technologies in computational protein design and synthetic biology. The company has created several genomically recoded strains of bacteria that enable the incorporation of non-standard amino acids into proteins. This approach enhances the potency, stability, and targeted delivery of these therapeutics. GRO Biosciences aims to apply its technology to improve treatments for a range of conditions, including diabetes, growth disorders, and autoimmunity, thereby addressing significant unmet medical needs.

Cellibre, Inc. is a cellular agriculture company based in San Diego, California, founded in 2017. The company specializes in transforming cells into sustainable production systems for significant global products. By employing an organism-agnostic approach, Cellibre develops natural medicines inspired by various cultural therapies and derived from a diverse range of biological sources, including plants, animals, insects, and marine life. This innovative methodology enables the healthcare industry to produce cannabinoid-based medicines, promoting efficient treatment options.

Olaris is dedicated to transforming disease diagnosis and treatment through its innovative CEREBRO platform, which integrates metabolomics and machine learning. This platform focuses on the Comprehensive Early Responsive Evaluation of Biomarkers Related to Outcomes, enabling the identification of biomarkers that can optimize patient treatment. By developing the myOLARIS™ precision diagnostics, Olaris aims to match the right drug to the right patient, enhancing clinical outcomes while minimizing adverse events. Founded in 2013 and headquartered in Framingham, Massachusetts, the company collaborates with healthcare providers to improve patient care through advanced diagnostic solutions.

Cyrus Biotechnology, Inc. is a Seattle-based company that specializes in developing advanced software for protein structure prediction and design. Founded in 2014, it offers several key products, including Rosetta, a tool designed to create biologically active proteins for various medical applications such as treating brain cancer and addressing Celiac Disease. The company also provides Cyrus Bench, an enterprise version of Rosetta that includes a comprehensive suite of bio-molecular computation tools. Additionally, Cyrus Biotechnology offers specialized services like Cyrus CryoEM, which focuses on structure refinement and model building for complex biomolecular structures. Its innovative software solutions cater to pharmaceutical companies, biotech firms, and startups engaged in discovering therapeutics and developing novel consumer products.

Veralox Therapeutics specializes in the development of small molecule therapeutics aimed at addressing the underlying pathologies of thrombosis and type one diabetes. The company focuses on innovative treatment paradigms informed by a deep understanding of the molecular mechanisms involved in these diseases. By targeting conditions such as heparin-induced thrombocytopenia and thrombosis, Veralox Therapeutics aims to enhance patient outcomes and facilitate complete recovery from diabetes. Through its research and development efforts, the company seeks to provide effective and transformative therapies for individuals affected by these serious health conditions.

Strateos specializes in automating chemistry, biology, and tissue analysis in closed-loop robotic labs, accelerating drug discovery programs for pharmaceutical partners. By combining advanced robotics, software for imaging and analytics, and remote cloud laboratories, Strateos enables more rapid and efficient discovery of new drug candidates. The company was formed through a merger of Transcriptic, which developed the first robotic cloud laboratory platform for life science research, and 3Scan, which specialized in automating tissue analysis. Strateos aims to express life science methods as data, enabling infrastructure virtualization and driving the next generation of discovery with significant time and cost efficiencies.

miRecule, Inc. is a biotechnology company based in Gaithersburg, Maryland, established in 2016. The company specializes in developing a microRNA-based drug discovery platform, DREAmiR, aimed at addressing challenges in cancer therapy and muscular dystrophy. This innovative platform leverages genomic and outcome data from thousands of patients to identify genetic abnormalities associated with diseases. miRecule formulates RNA therapeutics that can directly target and correct these genetic issues. The platform integrates genomic sequencing, expression, and prognostic data from numerous cancer patients with high throughput screening of microRNA candidates for replacement therapy. miRecule is focused on creating highly tailored therapeutics, with lead programs targeting Head & Neck Cancer and Facioscapulohumeral Muscular Dystrophy, ultimately striving to improve the quality of life for patients suffering from debilitating conditions.

Prima is a science-driven wellness brand focused on whole body health, offering a range of plant-based skincare, body care, and supplements that incorporate organic hemp CBD and functional botanicals. The company's mission is to address stress and other health issues at their source using clinically validated ingredients. Prima is committed to sustainability and transparency, as evidenced by its certifications as a Climate Neutral and Plastic Neutral company, in addition to being a certified B Corp. Headquartered in Santa Monica, California, Prima operates as a privately held Public Benefit Corporation, emphasizing the integration of science and nature in its products while promoting education and social impact in the wellness sector.

Gilgamesh Pharmaceuticals, Inc. is a preclinical biotechnology company based in New York that specializes in developing novel psychotropic drugs aimed at treating mental illnesses. Established in 2019, the company focuses on creating innovative compounds that enhance the therapeutic benefits of classic psychedelics while improving safety, tolerability, duration, and efficacy. Gilgamesh addresses the growing global mental health crisis by providing treatments for various neuropsychiatric conditions, including depression, anxiety, substance use disorders, and stress-related issues. Through a combination of medicinal chemistry and drug development expertise, the company aims to accelerate the availability of effective therapies, ultimately improving the quality of life for individuals suffering from central nervous system disorders.

Scipher Medicine Corporation is a biotechnology company based in Waltham, Massachusetts, that specializes in precision medicine for patients with autoimmune and cardiovascular diseases. The company has developed a molecular technology platform that utilizes blood samples to analyze RNA and predict patient responses to drug therapies. Its primary offerings include PrismDx tests, which identify patients who may not respond to certain medications, ensuring they can be prescribed alternative treatments. Notably, the PrismRA test assesses patients with rheumatoid arthritis to determine their likelihood of responding to anti-TNF therapies, while PrismUC serves a similar purpose for patients with ulcerative colitis. By focusing on the underlying disease biology rather than just symptoms, Scipher Medicine aims to optimize treatment from the outset, potentially reducing the healthcare costs associated with ineffective therapies. Established in 2013 and rebranded in 2015, Scipher Medicine is committed to transforming drug prescription practices and advancing drug development through its innovative approach.

InteRNA Technologies B.V. is a biotechnology company focused on the development of microRNA (miRNA)-based therapeutics for cancer treatment. The company's innovative approach leverages the unique properties of miRNAs to target previously undruggable pathways involved in cancer initiation, progression, and metastasis. By utilizing advanced techniques such as massively parallel sequencing and proprietary bioinformatics, InteRNA analyzes and validates miRNA sequences to enhance drug efficacy and reduce resistance to existing therapies. Founded in 2006, the company operates from Nijmegen, the Netherlands, and has a dedicated research and development center in Utrecht. Recently, InteRNA has secured additional equity financing to advance its lead program for melanoma treatment, demonstrating its commitment to developing novel solutions in oncology.

STIMIT AG is a medtech company based in Nidau, Switzerland, established in 2018. The company focuses on developing therapies and medical devices aimed at patients who have lost their natural breathing function, particularly those on mechanical ventilation. A significant portion of time in intensive care is dedicated to weaning patients off ventilators and restoring diaphragm function, which is critical for independent breathing. STIMIT's technology non-invasively activates the diaphragm, helping to keep it strong and functional, ultimately aiming to liberate patients from ventilators and reduce associated morbidity and mortality. Additionally, STIMIT is advancing a proprietary method for localized delivery of cancer immunotherapy, enhancing the efficacy and safety of treatment for patients with solid tumors. This dual focus positions STIMIT at the forefront of innovation in both respiratory care and oncology.

Concerto Biosciences specializes in rebuilding microbial communities to enhance human health and environmental sustainability. The company has developed an ultra-high-throughput platform capable of measuring millions of microbial interactions, enabling the mapping of complex inter-species networks that dictate community behavior. This innovation allows Concerto to create "ensembles," which are specific combinations of microbes that collaboratively promote the recovery of damaged microbial ecosystems. By focusing on these microbial ensembles, Concerto aims to address critical global issues across various sectors, including agriculture, healthcare, and industry. The company's pioneering work positions it as a leader in the development of microbial solutions, fundamentally changing how humanity interacts with microbial life.

Cultured Decadence is a startup based in Madison, Wisconsin, focused on cellular aquaculture to produce crustacean products. Founded in 2020, the company employs innovative cell culture and tissue engineering techniques to create lobster and crab meat directly from the animals' cells, eliminating shell, organs, and waste. This approach addresses the increasing global demand for sustainable and nutritious seafood, offering a more environmentally friendly alternative to traditional fishing methods.

Unlearn.AI, Inc. is a biotechnology company that specializes in developing software tools for clinical research, focusing on improving diagnosis and treatment processes. Based in San Francisco, the company offers solutions such as Clinical Trial Design, which helps define inclusion criteria, endpoints, and study sizes; Synthetic Control Arms, which reduce or eliminate the necessity for concurrent control groups; and Subgroup Analysis, which identifies specific patient subgroups within trial results. Unlearn.AI has pioneered the TwinRCT solution, a digital twin service that leverages machine learning to enhance the efficiency and success rates of clinical trials. This innovative approach creates a prognostic digital twin for each patient, allowing for more precise estimations of treatment effects based on historical data. By integrating machine learning and biostatistics, Unlearn.AI aims to accelerate the clinical trial process, benefiting both patients and pharmaceutical sponsors.

Arable Labs, Inc. specializes in developing a solar-powered Internet of Things (IoT) device equipped with advanced sensors for in-field crop monitoring. This technology allows farmers to digitize and optimize their agricultural decisions by providing critical data about the impact of weather and other factors on crop yield, quality, and harvest timing. Arable's integrated system combines unique spectral and thermal sensors with agronomic modeling and software tools, enabling users to monitor crop development and identify stressors such as water or nutrient deficiencies. The platform serves a diverse clientele, including farmers, agronomists, researchers, food processors, and agricultural enterprises, facilitating real-time insights and predictive analytics that enhance productivity and sustainability. Established in 2014, Arable is headquartered in San Francisco, California, with an additional office in Princeton, New Jersey. The company has received various accolades, highlighting its innovation in agricultural technology.

Ionobell is a battery research and development company that specializes in the advancement of battery materials and cell technology. With extensive expertise in energy storage, lithium-ion technology, and fabrication, the company focuses on creating environmentally friendly batteries. Ionobell has developed a unique approach to battery production by utilizing safe and abundant materials, including biomaterials, common plastic waste, and recycled components. This innovative technology aims to enhance the longevity and performance of batteries while maintaining cost-effectiveness and scalability. By replacing carbon with nano-particle silicon in the anode, Ionobell enables the production of batteries that offer improved energy density, faster charging times, and reduced environmental impact, catering to applications in unmanned aerial vehicles and electric vehicles.

Arable Labs, Inc. specializes in developing a solar-powered Internet of Things (IoT) device equipped with advanced sensors for in-field crop monitoring. This technology allows farmers to digitize and optimize their agricultural decisions by providing critical data about the impact of weather and other factors on crop yield, quality, and harvest timing. Arable's integrated system combines unique spectral and thermal sensors with agronomic modeling and software tools, enabling users to monitor crop development and identify stressors such as water or nutrient deficiencies. The platform serves a diverse clientele, including farmers, agronomists, researchers, food processors, and agricultural enterprises, facilitating real-time insights and predictive analytics that enhance productivity and sustainability. Established in 2014, Arable is headquartered in San Francisco, California, with an additional office in Princeton, New Jersey. The company has received various accolades, highlighting its innovation in agricultural technology.

Generate Biomedicines, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies through its unique platform. The company specializes in Generative Biology, a machine learning-driven approach that analyzes known proteins to understand the relationship between genetic sequences, protein structure, and function. This enables the creation of novel therapeutic proteins, including antibodies, enzymes, and receptors, which are designed to interact specifically and effectively with various therapeutic targets. Founded in 2018 and rebranded from Generate Biologics in 2020, Generate Biomedicines aims to streamline the drug discovery process by generating new biological molecules with significant therapeutic potential.

Brio Systems, Inc., established in 2017 and headquartered in Boston, Massachusetts, specializes in COVID-19 testing solutions for workplaces. Its comprehensive platform offers on-site PCR and antibody testing, logistical support, medical oversight, and digital results communication within three days. Brio connects employers with a network of FDA-certified labs, serving industries such as manufacturing and food processing. The company's secure platform also provides diagnostic testing services for individuals, focusing on blood metrics like sugar and hormone levels, offered on a monthly subscription basis.

Oobli specializes in the development of healthy, protein-based sweeteners sourced from exotic plants. These unique compounds offer a flavorful experience without the calories typically associated with sugar, making them a suitable alternative for health-conscious consumers. The protein sweeteners are produced through fermentation, ensuring they have no glycemic impact and do not disrupt the gut microbiome. Oobli has successfully obtained regulatory approvals, including FDA "no questions" letters and GRAS status for several of its proteins, reinforcing their commitment to safety and quality. By providing a delicious and low-calorie option, Oobli aims to transform the way individuals approach sweeteners, allowing for healthier choices in everyday consumption.

SCiFi Foods is a food technology company focused on producing cultivated meat that combines lab-grown beef cells with plant-based ingredients to create burgers that closely replicate the taste of traditional beef. The company aims to provide a sustainable and ethical alternative to conventional meat by utilizing bioengineering techniques to grow meat cells without relying on animal farming. SCiFi Foods has achieved significant advancements, including the successful growth of beef cells in suspension, which has the potential to drastically reduce production costs. Founded by CEO Joshua March and CTO Kasia Gora, PhD, the company has attracted $29 million in funding from prominent investors, positioning it for future growth in the alternative protein market.

Unlearn.AI, Inc. is a biotechnology company that specializes in developing software tools for clinical research, focusing on improving diagnosis and treatment processes. Based in San Francisco, the company offers solutions such as Clinical Trial Design, which helps define inclusion criteria, endpoints, and study sizes; Synthetic Control Arms, which reduce or eliminate the necessity for concurrent control groups; and Subgroup Analysis, which identifies specific patient subgroups within trial results. Unlearn.AI has pioneered the TwinRCT solution, a digital twin service that leverages machine learning to enhance the efficiency and success rates of clinical trials. This innovative approach creates a prognostic digital twin for each patient, allowing for more precise estimations of treatment effects based on historical data. By integrating machine learning and biostatistics, Unlearn.AI aims to accelerate the clinical trial process, benefiting both patients and pharmaceutical sponsors.

Endless West is a beverage startup focused on producing innovative wines and spirits using scientific methods. The company creates its products at a molecular level by extracting flavor, aroma, and color molecules from various plants and substances, eliminating the need for traditional ingredients like grapes and yeast. This approach allows Endless West to craft sustainable beverages without fermentation, significantly reducing the resources required for production, such as wood, water, and land. Its flagship product, Glyph, is an aged-style spirit that showcases this pioneering technique, offering consumers a unique drinking experience while promoting environmental sustainability.

Brio Systems, Inc., established in 2017 and headquartered in Boston, Massachusetts, specializes in COVID-19 testing solutions for workplaces. Its comprehensive platform offers on-site PCR and antibody testing, logistical support, medical oversight, and digital results communication within three days. Brio connects employers with a network of FDA-certified labs, serving industries such as manufacturing and food processing. The company's secure platform also provides diagnostic testing services for individuals, focusing on blood metrics like sugar and hormone levels, offered on a monthly subscription basis.

Mission Bio, Inc. is a biotechnology company that specializes in tools for studying cellular heterogeneity in human health and life sciences. The company has developed the Tapestri Platform, the first single-cell multi-omics platform, which allows for the simultaneous analysis of genotype and phenotype from the same cell. This platform utilizes proprietary microfluidic droplet technology to enable precise detection of genomic variability at single-cell resolution, facilitating research in various applications, including oncology, blood cancers, solid tumors, and genome editing. Additionally, Mission Bio offers Tapestri Designer, a cloud-based tool for creating customized single-cell DNA panels, further enhancing its capabilities in targeted molecular analysis. Founded in 2011 and based in South San Francisco, California, the company was previously known as Torrent Bio, Inc. before rebranding in 2013.

Emulate, Inc. specializes in organ-on-chip technology that simulates human biology to enhance the understanding of how diseases, medications, chemicals, and food impact human health. The company develops organ-chips for various organs, including the lung, intestine, liver, and skin, which replicate normal functions and disease conditions. Emulate's innovative technology offers researchers a more accurate alternative to traditional experimental methods, such as cell cultures and animal testing, by providing detailed insights into human biological responses. Additionally, the company supplies drug development and instrumentation software to facilitate research and development workflows for its clients. Emulate serves a diverse range of sectors, including biotechnology, pharmaceuticals, consumer health, cosmetics, chemicals, food, agrochemicals, government agencies, and academic institutions. Founded in 2013 and headquartered in Boston, Massachusetts, Emulate was previously known as Emulate Living MicroDevices, Inc. until its name change in 2014.

Emulate, Inc. specializes in organ-on-chip technology that simulates human biology to enhance the understanding of how diseases, medications, chemicals, and food impact human health. The company develops organ-chips for various organs, including the lung, intestine, liver, and skin, which replicate normal functions and disease conditions. Emulate's innovative technology offers researchers a more accurate alternative to traditional experimental methods, such as cell cultures and animal testing, by providing detailed insights into human biological responses. Additionally, the company supplies drug development and instrumentation software to facilitate research and development workflows for its clients. Emulate serves a diverse range of sectors, including biotechnology, pharmaceuticals, consumer health, cosmetics, chemicals, food, agrochemicals, government agencies, and academic institutions. Founded in 2013 and headquartered in Boston, Massachusetts, Emulate was previously known as Emulate Living MicroDevices, Inc. until its name change in 2014.

Gallant Pet, Inc. is a pet service company based in San Diego, California, that specializes in stem cell preservation services for dogs. Founded in 2018, the company collects and banks stem cells from tissue during routine spay or neuter procedures. Gallant Pet also provides a platelet-rich plasma (PRP) kit for dogs suffering from osteoarthritis and other musculoskeletal issues. In addition to its preservation services, the company is engaged in clinical research to develop effective stem cell therapies for various conditions. Through its innovative approach, Gallant Pet enables pet owners to preserve their pets' young stem cells for future medical treatments.

Excision BioTherapeutics Inc. is a life science company based in Philadelphia, Pennsylvania, established in 2015. The company specializes in developing gene editing therapeutics aimed at treating life-threatening diseases caused by neurotropic viruses. Utilizing CRISPR-based technology, Excision BioTherapeutics focuses on creating advanced gene-editing medicines that can eradicate or disrupt viral genes in human patients. The company is committed to advancing these therapeutics to ensure they are safe and effective, with the goal of significantly improving the lives of individuals affected by viral infections worldwide.

SQZ Biotech is a clinical-stage biotechnology company focused on developing innovative cell therapies for patients facing cancer, infectious diseases, and other serious health conditions. Utilizing its proprietary CellSqueeze technology, SQZ Biotech can deliver a variety of materials into diverse patient cell types, enabling the engineering of therapies that address a wide array of clinical challenges. The company aims to create well-tolerated cell therapies that not only enhance therapeutic benefits but also improve the overall patient experience compared to traditional cell therapy methods. Through a combination of internal research initiatives and external collaborations, SQZ Biotech is advancing a new generation of cellular therapies aimed at both immune activation and immune suppression.

Notable Labs, Inc. is a clinical-stage company that specializes in personalized lab testing services for cancer patients, particularly those with brain cancer. Founded in 2014 and based in Foster City, California, the company utilizes its proprietary Predictive Precision Medicines Platform to conduct drug combination experiments on patients' tumors. This platform allows Notable Labs to simulate cancer treatments and predict patient responses to specific therapies, enabling healthcare providers to prioritize combinations of FDA-approved treatments that can be prescribed without the need for clinical trials. By providing detailed reports to physicians, Notable Labs aims to enhance treatment efficacy and expedite therapeutic development for patients.

miRecule, Inc. is a biotechnology company based in Gaithersburg, Maryland, established in 2016. The company specializes in developing a microRNA-based drug discovery platform, DREAmiR, aimed at addressing challenges in cancer therapy and muscular dystrophy. This innovative platform leverages genomic and outcome data from thousands of patients to identify genetic abnormalities associated with diseases. miRecule formulates RNA therapeutics that can directly target and correct these genetic issues. The platform integrates genomic sequencing, expression, and prognostic data from numerous cancer patients with high throughput screening of microRNA candidates for replacement therapy. miRecule is focused on creating highly tailored therapeutics, with lead programs targeting Head & Neck Cancer and Facioscapulohumeral Muscular Dystrophy, ultimately striving to improve the quality of life for patients suffering from debilitating conditions.

Allevi develops innovative tools for designing and engineering 3D tissues, focusing on bioprinting technology. The company offers desktop 3D bioprinters that allow users to create functional three-dimensional living tissues using various biomaterials and cell lines. Additionally, Allevi provides bioinks made from collagen and hyaluronic acid, which are available for purchase online. Their cloud-based platform, Bioprint Online, enables users to design complex structures, define materials, and monitor the printing process. Allevi's products serve a diverse clientele, including researchers in tissue engineering, regenerative medicine, and cell biology, as well as industrial and pharmaceutical companies for drug testing and development, and educators. Established in 2014 and based in Philadelphia, Pennsylvania, Allevi was formerly known as BioBots, Inc.